INS and Hypoglycemia: In our model, basal insulin replacement was provided by subcutaneous insulin implants (LinBit), which we have shown previously are sufficient to prevent metabolic decompensation [19], while recurrent hypoglycaemia was induced at planned intervals with rapid-acting insulin.